To investigate whether Plk1 is a suitable target in HCC, its therapeutic effectiveness of Plk1 inhibition was compared in 3 different models: HCC cell lines, nude mice xenografted with HCC, and in a transgenic mouse model (TGF α/c-myc) evolving HCC endogenously [259]. This evidence concerns the gene MYC and hepatocellular carcinoma.